Stock Events

Stock Events

Cortexyme

$1.9500

64

+$0.05+2.63% Friday 22:00

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

18NovExpected

Q4 2024

Q1 2025

Q2 2025

Q3 2025

Q1 2026

Q2 2026

Next

-28.02

6.52

41.06

75.6

Expected EPS

-1.126667

Actual EPS

N/A

Financials

-Profit Margin

Unprofitable

2018

2019

2020

2021

0Revenue

-156.49MNet Income

Analyst Ratings

52.00Average Price Target

The highest estimate is 82.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.

Buy

100%

Hold

0%

Sell

0%

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

CRISPR Therapeutics

CRISPR Therapeutics AG focuses on the development of gene-based medicines, including therapies for genetic diseases, competing in the same innovative healthcare space as Quince.

Editas Medicine

Editas Medicine, Inc. works on editing genes to treat genetic diseases, directly competing with Quince's approach to addressing genetic disorders.

Intellia Therapeutics

Intellia Therapeutics, Inc. is a leading developer of CRISPR/Cas9 gene-editing therapies for genetic diseases, making it a direct competitor in the genetic medicine field.

Voyager Therapeutics

Voyager Therapeutics, Inc. specializes in the development of gene therapies for neurodegenerative diseases, competing in the broader market of genetic disorder treatments.

Protagonist Therapeutics

Protagonist Therapeutics, Inc. is engaged in the discovery and development of novel peptide-based drugs, which could compete with Quince's therapeutic approaches in a broader sense.

Fate Therapeutics

Fate Therapeutics, Inc. is involved in the development of programmed cellular immunotherapies for cancer and immune disorders, competing in the innovative treatment space.

REGENXBIO Inc. focuses on the development, commercialization, and licensing of recombinant adeno-associated virus (AAV) gene therapy, which competes with Quince's focus on regenerative medicine and genetic therapies.

About

Biotechnology

Health Technology

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on advancing precision therapeutics for debilitating and rare diseases. The company has discovered a broad bone-targeting drug platform to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease. Its lead compound is NOV004, an anabolic peptide engineered to precisely target and concentrate at the bone fracture site The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Show more...

CEO

Employees

37

Country

United States

ISIN

US22053A1079

Listings

0 Comments

Share your thoughts

FAQ

What is Cortexyme stock price today?▼

The current price of CRTX is $1.95 USD — it has increased by +2.63% in the past 24 hours. Watch Cortexyme stock price performance more closely on the chart.

What is Cortexyme stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Cortexyme stocks are traded under the ticker CRTX.

What were Cortexyme earnings last quarter?▼

CRTX earnings for the last quarter are 0 USD per share, whereas the estimation was -0.29 USD resulting in a +100% surprise. The estimated earnings for the next quarter are N/A USD per share.

What is Cortexyme revenue for the last year?▼

Cortexyme revenue for the last year amounts to 0 USD.

What is Cortexyme net income for the last year?▼

CRTX net income for the last year is -156.49M USD.

How many employees does Cortexyme have?▼

As of September 10, 2026, the company has 37 employees.

In which sector is Cortexyme located?▼

Cortexyme operates in the Technology sector.

When did Cortexyme complete a stock split?▼

Cortexyme has not had any recent stock splits.